Education
About Us
Working with TipRanks
Follow Us
NewAmsterdam Pharma Company (NAMS)
NASDAQ:NAMS
RESEARCH TOOLSreports
NAMS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$14.06 - $27.29
Previous CloseN/A
Volume118.30K
Average Volume (3M)610.93K
Market Cap
$1.98B
Enterprise Value$1.29B
Total Cash (Recent Filing)$834.19M
Total Debt (Recent Filing)$448.00K
Price to Earnings (P/E)―
Beta1.80
Next Earnings
Aug 12, 2025EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding112,270,676
10 Day Avg. Volume547,278
30 Day Avg. Volume610,931
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)2.35
Price to Sales (P/S)0.00
P/FCF Ratio-13.58
Enterprise Value/Market Cap0.65
Enterprise Value/Revenue13.91
Enterprise Value/Gross Profit28.50
Enterprise Value/Ebitda-1.67
Forecast
1Y Price Target
$42.43Price Target Upside140.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
NewAmsterdam Pharma Company News
PremiumCompany Announcements
NewAmsterdam Pharma Reports Q1 2025 Financial Results
PremiumCompany Announcements
NewAmsterdam Pharma Presents Promising Phase 3 Trial DataBulls Say, Bears Say
Bulls Say
Clinical TrialsThe exploratory analysis from BROADWAY showed a compelling 21% reduction in 4-point MACE after just one year of treatment, reinforcing a positive outlook on the stock.
Drug EfficacyObicetrapib's ability to offer multi-modal mechanisms of cardiovascular risk reduction in a single once-daily oral pill affords compelling commercial advantages over other lipid-lowering drugs in development.
Financial PerformanceObicetrapib could achieve peak revenues of approximately $3 billion in the US alone, supporting a positive view on the stock setup.
Bears Say
Endpoint UncertaintyInvestors have questioned the breakdown of the MACE endpoints, given the benefit was largely driven by urgent coronary revascularizations.
Investment TimingThe major CVOT catalyst isn't until late 2026 or early 2027 and there isn't huge urgency to own the stock now.
Trial ResultsStroke was the only component that was numerically higher in the treatment arm in the BROADWAY trial.
Ownership Overview
16.67% Insiders
7.62% Mutual Funds
2.64% Other Institutional Investors
72.21% Public Companies and Individual Investors
NAMS FAQ
What was NewAmsterdam Pharma Company’s price range in the past 12 months?
NewAmsterdam Pharma Company lowest stock price was $14.06 and its highest was $27.29 in the past 12 months.
What is NewAmsterdam Pharma Company’s market cap?
NewAmsterdam Pharma Company’s market cap is $1.98B.
When is NewAmsterdam Pharma Company’s upcoming earnings report date?
NewAmsterdam Pharma Company’s upcoming earnings report date is Aug 12, 2025 which is in 76 days.
How were NewAmsterdam Pharma Company’s earnings last quarter?
NewAmsterdam Pharma Company released its earnings results on May 08, 2025. The company reported -$0.345 earnings per share for the quarter, beating the consensus estimate of -$0.368 by $0.023.
Is NewAmsterdam Pharma Company overvalued?
According to Wall Street analysts NewAmsterdam Pharma Company’s price is currently Undervalued.
Does NewAmsterdam Pharma Company pay dividends?
NewAmsterdam Pharma Company does not currently pay dividends.
What is NewAmsterdam Pharma Company’s EPS estimate?
NewAmsterdam Pharma Company’s EPS estimate is -0.49.
How many shares outstanding does NewAmsterdam Pharma Company have?
NewAmsterdam Pharma Company has 112,270,676 shares outstanding.
What happened to NewAmsterdam Pharma Company’s price movement after its last earnings report?
NewAmsterdam Pharma Company reported an EPS of -$0.345 in its last earnings report, beating expectations of -$0.368. Following the earnings report the stock price went up 1.85%.
Which hedge fund is a major shareholder of NewAmsterdam Pharma Company?
Currently, no hedge funds are holding shares in NAMS
NewAmsterdam Pharma Company Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.43 (140.94% Upside)
$42.43 (140.94% Upside)
Blogger Sentiment
Bullish
NAMS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.80%
12-Months-Change
Fundamentals
Return on Equity
-31.51%
Trailing 12-Months
Asset Growth
67.55%
Trailing 12-Months
Company Description
NewAmsterdam Pharma Company
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
NAMS Stock 12 Month Forecast
Average Price Target
$42.43
▲( 140.94% Upside)
Technical Analysis
Denali Therapeutics
―
Arcutis Biotherapeutics
―
Harmony Biosciences Holdings
―
Recursion Pharmaceuticals
―
Metsera, Inc.
―